TVT, also known as infectious sarcoma, venereal granuloma, transmissible lymphosarcoma or sticker tumour is a benign reticuloendothelial tumour that affects particularly mucosa of external genital organs and rarely internal genital organs in dogs of both genders. TVT is usually transmitted by coitus but also can be transmitted by licking, sniffing, biting,and scrabbling of the tumour affected area or through damaged skin of mucosa. Transmissible venereal tumour (TVT) is usually observed in stray animals live in tropical and subtropical lands. The affected animals are usually within 9-13 months of age and with high sexual activity. Tumour is frequently located in posterior vagina and vestibulovaginal junction. The averagechromosome count of TVT cells is 59 (57- 64). TVT specific antibodies were found in blood samples of affected animalswhich suggest that they may have a role in natural regression mechanism. The primary objective of tumour treatment is total elimination by surgery, radiotherapy, immunotherapy and/or chemotherapy. Controlling of the disease is very difficult because stray dogs are carriers.

Objective-To determine the maximum tolerated dose and characterize the pharmacokinetic disposition of an orally administered combination of docetaxel and cyclosporin A (CSA) in dogs with tumors. Animals-16 client-owned dogs with metastatic or advanced-stage refractory tumors. Procedures-An open-label, dose-escalation, single-dose, phase I study of docetaxel administered in combination with a fixed dose of CSA was conducted. Docetaxel (at doses of 1.5, 1.625, or 1.75 mg/kg) and CSA (5 mg/kg) were administered concurrently via gavage twice during a 3-week period. Plasma docetaxel concentrations were quantified by use of high-performance liquid chromatography, and pharmacokinetic disposition was characterized by use of noncompartmental analysis. Dogs' clinical signs and results of hematologic and biochemical analyses were monitored for evidence of toxicosis. Results-No acute hypersensitivity reactions were observed after oral administration of docetaxel. Disposition of docetaxel was dose independent over the range evaluated, and pharmacokinetic variables were similar to those reported in previous studies involving healthy dogs, with the exception that values for clearance were significantly higher in the dogs reported here. The maximum tolerated dose of docetaxel was 1.625 mg/kg. Gastrointestinal signs of toxicosis were dose limiting. Conclusions and Clinical Relevance-The absence of myelosuppression suggested that the docetaxel-CSA combination may be administered more frequently than the schedule used. Further studies are warranted to evaluate combination treatment administered on a biweekly schedule in dogs with epithelial tumors.

Hemorrhagic shock was induced in nonsplenectomized dogs by removing 41% of their blood volume over a 15-minute period. Hemodynamic and metabolic variables were determined prior to and for 3 hours after completion of hemorrhage. One group of 5 dogs was not treated. After the 30-minute sample was collected, a second group of 5 dogs was given lactated Ringer solution (LRS) at 88 ml/kg of body weight, IV. A third group of 5 dogs was given LRS (88 ml/kg, IV) and prednisolone sodium succinate (11 mg/kg, IV) 30 minutes after hemorrhage. The IV administration of LRS was completed within 15 minutes. The glucocorticoid was administered as an IV bolus after 500 ml of LRS had been given. The large volume and administration of LRS significantly (P = 0.05) improved many of the hemodynamic and metabolic effects of acute hemorrhage and hemorrhagic shock. At one time or another during the 2.5-hour observation period after the initiation of treatment, mean arterial pressure, cardiac index, systemic vascular resistance, heart rate, respiratory rate, lactate, glucose, and arterial and venous blood gas values were significantly (P = 0.05) improved, compared with baseline values. The addition of prednisolone sodium succinate to the treatment regimen improved the effectiveness of LRS alone only in some dogs at random sampling times. Significant trends were not observed except, possibly, the improvement of venous pH and A-V pH and P(CO)2 differences.

Tumors of the mammary glands are the most common neoplasms in dogs in our country; however, there are few Brazilian reports dedicated to clinicopathological and survival studies about this disease. This report aims the clinical and pathological study of canine mammary tumors in the Santos Metropolitan Region, an area in Sao Paulo state with an estimated canine population of 120,000 animals. Data of 14,298 dogs were collected retrospectively from the medical records of the Veterinary Medical Teaching Hospital of the Metropolitan University of Santos – São Paulo – Brazil. During the study period, from records of 317 females with histopathological diagnosis of neoplasia, 170 were mammary epithelial lesions distributed in 13 benign tumors, 152 malignant (89.4% of diagnosis) and 5 non-neoplasic epithelial lesions (ductal hyperplasia). The highest prevalent malignant tumor was tubular carcinoma (38.2% of diagnosis) and Grade I tumors, corresponding to 73.0% of all diagnosis. The results have shown clinical staging of canine mammary neoplasms as an important prognostic survival factor and, in a multivariate analysis, tumor diameter, tumor grade, adjuvant chemotherapy and recurrence as covariates with predictive value for survival. Moreover, the high prevalence of tubular carcinoma qualifies the canine population ofSantosas a promising model for the translational study of this disease.

In breast cancer treatment, chemotherapy resistance is a major problem where many receptive tumors rebound and develop resistance. When provided in combination, cancer drugs are most successful, thus reducing the risk of developing resistant cancer cells. However, the evaluation of combination therapies has increased rapidly in recent years. Consequently, by repurposing old treatments, the discovery of additional medicines that may interact synergistically with chemotherapy is considered a current medical aim through discovering a new cancer medication or therapeutic strategy. The purpose of this research is to increase the anti-cancer activity of carboplatin (CP) by increasing the apoptotic effect of breast cancer cells (MCF-7) during in vitro experiments in combination with oxytetracycline. Our results showed a high synergistic effect between oxytetracycline and carboplatin, MCF-7 representative cell treated with carboplatin with/without different concentrations of oxytetracycline (5% and 10% of IC50). Oxytetracycline, which potentiated the action of carboplatin and/or had notable activity was reported as a single agent. This research demonstrated the synergistic relationship between oxytetracycline and carboplatin in viability assays. Surprisingly, our findings suggest that inhibiting treatment strategies can extend carboplatin’s therapeutic window, potentially allowing for cancer therapy.

Chemotherapy agents have some undesirable and non-selective cytostatic effects. Considering that kidneys are vulnerable to drug-induced toxicity, this study evaluated renal injury caused by vincristine sulfate (VS) in 12 female dogs diagnosed with transmissible venereal tumor (TVT). The animals were treated with VS (0.025 mg/kg IV) every 7 days for 4 weeks. During treatment, the animals were subjected to clinical examination, blood count, serum measurement of symmetric dimethylarginine (SDMA), blood urea nitrogen (BUN), creatinine, alanine aminotransferase, and alkaline phosphatase. In addition, urinalysis and urinary gamma-glutamyl transferase (GGT) measurements were performed. All parameters were determined three times: before beginning the treatment (T0), after 14 days (T1), and after 28 days (T2). During the study period, there were no changes in serum urea or creatinine levels, urine specific gravity, or persistent proteinuria. Furthermore, urinary GGT measurement did not indicate tubular lesions, and consistent elevation of SDMA was found in only one patient above the reference range. The results showed that weekly therapy with VS as a single agent for 28 days does not induce renal injury in most cases.